Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Common Equity (2020 - 2025)

Biofrontera has reported Common Equity over the past 6 years, most recently at $10.5 million for Q4 2025.

  • For Q4 2025, Common Equity rose 136.41% year-over-year to $10.5 million; the TTM value through Dec 2025 reached $10.5 million, up 136.41%, while the annual FY2025 figure was $10.5 million, 136.41% up from the prior year.
  • Common Equity for Q4 2025 was $10.5 million at Biofrontera, up from -$2.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $23.9 million in Q4 2022 and troughed at -$17.4 million in Q3 2021.
  • A 5-year average of $6.2 million and a median of $5.2 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: surged 1359.72% in 2022 and later plummeted 146.67% in 2025.
  • Year by year, Common Equity stood at $11.3 million in 2021, then surged by 110.6% to $23.9 million in 2022, then crashed by 79.93% to $4.8 million in 2023, then dropped by 7.51% to $4.4 million in 2024, then soared by 136.41% to $10.5 million in 2025.
  • Business Quant data shows Common Equity for BFRI at $10.5 million in Q4 2025, -$2.6 million in Q3 2025, and -$4.7 million in Q2 2025.